skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Good afternoon,
Looking to add US healthcare to my portfolio. I would appreciate your thoughts and ranking on the following US healthcare and service providers; MCK, BDX, SYK, UNH, HUM and MDT. I am open to other recommendations.
Thank you,
Patrick
Read Answer Asked by Patrick on December 09, 2019
Q: Kalvista flunked a drug trial and the stock was down 20% premarket. Now the stock is up 4%. Any idea why?
Read Answer Asked by hal on December 09, 2019
Q: Dear 5i,
I would appreciate you comments on the following questions:
1. Does key management have meaningful share ownership in the company?
2. How long has key management been at the helm?
3. Would you expect any further dividend cuts?
4. Do you think their debt is manageable and reasonable?
5. Do they own any real estate. If yes, how much worth?

thanks
Read Answer Asked by Ian on December 09, 2019
Q: NXPI along with KODIAK Science which is up more than 100% in the last month, what are your opinions of the two stocks?
About the PE ratio - on my Globe Invest it has for instance 98.4 TTM (I do not know what that is), is that number too high for you if you were looking to purchase a stock with that number? What would be a more comfortable number? Thanks for providing info that the average investor would not know. Dennis
Read Answer Asked by Dennis on December 09, 2019
Q: Listed on Nasdaq as AUPH. After market close today,it was halted pending news.Later it announced positive phase 3 trail results showing that its Voclosporin is much better than Standard of Care in Lupus Nephritis.It plans to file NDA submission to FDA in 1st half of 2020,There will be a conference call @ 8.30am ET on Dec 5 .AUPH closed @ US$8.39 up 0.41 on 4.9m shares.However in After Hours trading it was @ US $18.39 to US$19.00 on total 10.6m shares.Thinking of selling my 1.5% position,p/p Can$8.33 especially if the Price is around US$18.39 to 19.00.Should I sell all or partial.Please provide your usual great advices & services.Thanks
Read Answer Asked by Peter on December 05, 2019
Q: I have been very fortunate to have my second 10-bagger with ARWR bought at $4 in 2017 (after some earlier losses). It has been running very well recently but is down to-day on the news that they are issuing 4m shares at $58, well below yesterdays close of $68.66. Why would they issue new shares so far below the recent market? Is there something here to worry about?
Thanks for your great service, Bob.
Read Answer Asked by Lynn on December 04, 2019
Q: Gud has now 51% and yet BIO trades at $10.15 BRL, about 16% below the offer price.
What do you read into this. Is there an opportunity here ? Can I buy BIO, should I ?
Will GUD offer less than they offered the private previous owners ? When will GUD start reporting earnings from this acquisition ? Do they need all the shares to do so ?
Finally do you see more analysts stepping in now with this new acquisition, maybe one or two will make it their top pick in 2020 ? Thoughts?Thanks
Read Answer Asked by Luc on December 03, 2019
Q: Hi there,

This is a cancer biotech focused on melanoma and cervical cancer. It sounds like several promising trials are underway. I just read about it on Seeking Alpha and CNBC shows 8 analysts covering with 5 strong buy and 3 buy recommendations with a consensus target of $35 vs a current price of $22.83. What are your thoughts regarding a position within a TFSA?

ThanksQ
Read Answer Asked by Tim on December 03, 2019
Q: Hi Peter and Ryan,

I noticed CLVS had a good run lately. I am wondering whether the fundamental has been changed. Is it a good buy now?
Please also provide a few (CAD and US) names that are stable for long investment in the next few months, particularly with good valuation. It is almost RRSP season.
Thanks,
Yiwen
Read Answer Asked by Yiwen on November 29, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!